Genetic testing may reveal the cause of sudden death in a young person
14.9.2026 09:18:15 EEST | HUS | Press release
The reason for an unexplained sudden death of a young person may be a rare hereditary disease that can remain undetected in standard examinations. Genetic testing is an important part of investigating the cause of an unexpected sudden death, especially in adolescents. Genetic testing may also help to identify relatives who are at risk of sudden death, and to prevent possible severe cardiac events.

One such rare hereditary disease is associated with a defect in the gene PPA2. It may cause extreme sensitivity to alcohol and increase the risk of severe, or even fatal cardiac events.
A recent Finnish study provides new information on this disease. The study found that a person with the PPA2 gene defect may be completely asymptomatic well into adulthood. However, the first sign of the disease may be a severe cardiac event. The cardiac event may be triggered by a very small amount of alcohol.
“The PPA2 disease may cause no symptoms for a very long time, and a severe cardiac event may be the first symptom. If the gene defect is identified before this, the risk can be reduced in a simple but very important way, which is abstinence from alcohol”, explains Postdoctoral Researcher Krista Heliö.
A recommendation in the journal Circulation, published by the American Heart Association, states that carriers of the PPA2 gene defect should abstain from alcohol completely. The extreme sensitivity to alcohol associated with the PPA2 disease means that even minor amounts of alcohol can trigger a severe cardiac event.
Genetic diagnosis provides important information for the entire family
The study emphasizes the importance of postmortem genetic testing when the sudden death of a young individual is otherwise unclear. A rare hereditary disease is not always detected in a regular autopsy.
Identifying a gene defect may help find out the cause of the death and also lead to genetic testing of the living relatives. This can help identify individuals who share the same hereditary risk of a severe cardiac event.
“An unexplained sudden death of an adolescent is always a terrible tragedy for the family. Uncertainty over the cause of death may become a long-term burden. If a hereditary condition can be identified as the cause, the information can be used to protect other family members. The PPA2 disease is a mitochondrial disorder, which can sometimes manifest exclusively as a cardiac condition. This is one example that shows why genetic testing in these situations is important”, says Tiina Ojala, professor of pediatric cardiology.
“The extreme sensitivity to alcohol associated with the PPA2 disease is an example of a very rare hereditary condition that is associated with a risk of a fatal cardiac event. There are other, far more common, hereditary cardiac arrhythmias and myocardial diseases, which may cause a sudden cardiac death, and they can be detected with genetic testing,” explains Associate Professor Tiina Heliö.
This study was conducted by a multidisciplinary research group from HUS, University of Helsinki, and Tampere University. Postdoctoral Researcher Krista Heliö was responsible for the implementation of the study, and Associate Professor Tiina Heliö and Professor of Pediatric Cardiology Tiina Ojala were responsible for supervision.
In university hospitals research is part of treatment: new research outcomes make treatment practises more efficient and help focus treatments correctly. We work in close collaboration with the University of Helsinki and other universities, and we publish ca 3,000 peer-reviewed research articles annually.
Today’s research provides better care in the future.
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
Keywords
Contacts
Professor Tiina Ojala, tel. +35850 4270558 tiina.h.ojala@hus.fi
HUS New Children's Hospital and University of Helsinki
Associate Professor Tiina Heliö, tel. +35850 428 6589, tiina.helio@hus.fi
HUS Heart and Lung Center and University of Helsinki
Links
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our more than 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Sammanslutningens styrelse valde HUS nya leverantör av bilddiagnostisk lösning5.10.2026 13:16:05 EEST | Pressmeddelande
På sitt möte valde sammanslutningens styrelse HUS nya leverantör av bilddiagnostisk lösning och behandlade verksamheten och ekonomin för januari–augusti 2026.
Yhtymähallitus valitsi HUSin kuvantamisratkaisun toimittajan5.10.2026 13:16:05 EEST | Tiedote
Yhtymähallitus valitsi kokouksessaan HUSin kuvantamisratkaisun toimittajan sekä käsitteli tammi−elokuun 2026 toimintaa ja taloutta.
Studie gav ny kunskap om immunförsvaret vid leukemi29.9.2026 08:26:54 EEST | Pressmeddelande
Forskare vid HUS Cancercentrum och Helsingfors universitet utredde hur immunsystemet hos patienter med akut myeloisk leukemi reagerade på experimentell immunterapi. Förändringar som hänför sig till terapiresponsen visade sig i andra immunceller än förväntat baserat på tidigare studier.
Tutkimus toi uutta tietoa leukemian immuunipuolustuksesta29.9.2026 08:26:54 EEST | Tiedote
HUSin Syöpäkeskuksen ja Helsingin yliopiston tutkijat selvittivät, miten akuuttia myelooista leukemiaa sairastavien potilaiden immuunijärjestelmä reagoi kokeelliseen immunoterapiaan. Hoitovasteeseen liittyvät muutokset näkyivät eri immuunisoluissa kuin aiempien tutkimusten perusteella olisi voitu odottaa.
Study provides new insights into the immune response in leukemia29.9.2026 08:26:54 EEST | Press release
Researchers at HUS Comprehensive Cancer Center and the University of Helsinki investigated how the immune systems of patients with acute myeloid leukemia (AML) respond to experimental immunotherapy. The study found that changes associated with treatment response were observed in different immune cell types than would have been expected based on previous research.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom